The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Alpha-Synuclein Aggregates as an Inducer of Glial Senescence: Potential Role in Parkinson's Disease
Study Rationale:
Cellular senescence (deterioration) is a critical factor of biological aging that occurs in almost all peripheral tissues but little is known about its... -
Therapeutic Pipeline Program, 2016Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia
Study Rationale:
Up to 80% of individuals with Parkinson’s develop Parkinson’s disease dementia (PDD), which is characterized by a progressive loss of memory and a decline... -
Target Advancement Program, 2016Genetic Modulation of LAMP-2A in PD Models
Study Rationale:
Brain cells use surveillance mechanisms to get rid of toxic proteins, such as mutant alpha-synuclein, that otherwise would accumulate and kill them. We have... -
Target Advancement Program, 2016Mechanism of TFEB Dysfunction by GBA1 Mutation in Human iPSC-derived Dopaminergic Neurons
Study Rationale:
People who have mutations in the GBA1 gene have a higher chance of developing Parkinson's disease (PD) but it is unclear why. We found that GBA1 mutations affect the cellular ability... -
PPMI Data Challenge, 2016Subtyping Parkinson’s Disease with Deep Learning Models (2016 PPMI Data Challenge Winner)
Study Rationale:
As Parkinson's disease (PD) is highly heterogeneous, identifying coherent PD subtypes is crucial for understanding the underlying mechanism of the disease and designing and testing... -
PPMI Data Challenge, 2016Multivariate Prediction of Parkinson's Disease Clinical Progression (2016 PPMI Data Challenge Winner)
Study Rationale:
Parkinson's disease (PD) is heterogeneous in both clinical representation and prognosis, as indicated by a large diversity of rates of progression in motor as well as non-motor...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.